---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-26-000096"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2026-08-06T20:03:19+00:00"
generated_at: "2026-08-06T20:04:08.689333+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Denali Q2 net loss $127.6M; AVLAYAH revenue $3.6M; PRV sale adds $195M; DNL151 discontinued in idiopathic PD

## Summary
- Q2 2026 net loss $127.6M vs $124.1M YoY; R&D $97.0M, SG&A $36.3M.
- AVLAYAH (Hunter syndrome) first full quarter net revenue $3.6M; Q3 guidance $10-12M.
- PRV sale closed July 2026 for $195M gross; pro forma cash >$1.1B.
- DNL151 (Parkinson's) Phase 2b LUMA failed; development in idiopathic PD discontinued; BEACON study for LRRK2 carriers continues.
- DNL593 (FTD-GRN) results delayed to 2027; Takeda terminated collaboration in April (strategic).

## SEC filing metadata
- accession: 0001714899-26-000096
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2026-08-06T20:03:19+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000096/0001714899-26-000096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000096/dnli-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-26-000096
- JSON: https://secwatch.observer/filing/0001714899-26-000096.json
- Plain text: https://secwatch.observer/filing/0001714899-26-000096.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.